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The photophysical properties of S-flurbiprofen [S-2-fluoro-α-methyl-4-biphenylacetic acid], a nonsteroidal anti-
inflammatory drug, have been examined using steady-state and time-resolved spectroscopic techniques.  The energy of its 
first singlet excited state is 99 kcal mol-1. The fluorescence quantum yields and lifetimes (at 300 nm) have been 
determined in acetonitrile, methanol, hexane and PBS; they are in the range 0.15<φF<0.33 and 0.7<τF<2.0 ns. The 
intersystem crossing quantum yields are between 0.45 and 0.71; the λmax of the T-T absorption is 360 nm, and the triplets 
live from 15 to 106 µs.  Steady state photolysis in aqueous medium leads to S-2-hydroxy-α-methyl-4-biphenylacetic acid 





acid] (Chart 1) is a nonsteroidal anti-inflammatory drug 
(NSAID). It has been widely used for several medical 
purposes, such as treatment of inflammation and pain 
caused by rheumatoid arthritis,1 osteoarthritis2 and soft 
tissue injuries (tendinitis and bursitis),3 prevention of 
migraine headache,4 treatment of sunburn5 and acute gout6 








             Chart 1 
 
The pharmacological effects of S-flurbiprofen (FBP) 
are associated with inhibition of prostaglandin H2 synthase 
(also named cyclooxygenase or COX), which exists in two 
isoforms (COX-1 and COX-2) and is the enzyme  
responsible for the catalytic conversion of arachidonic 
acid into prostaglandin H2, a key intermediate in the 
biosynthetic pahtway of prostaglandins, prostacyclins and 
thromboxanes.8  
S-Flurbiprofen has been used as a probe to displace 
fluorescent cyclooxygenase inhibitors from the active 
sites; emission variations provide valuable information on 
the interactions of such inhibitors with COX-1 and COX-
2.9 Moreover, the intrinsic fluorescence of FBP has been 
shown to be a useful tool for the study of the interaction 
between  the drug and human serum albumin, as well as 
for the characterisation of the binding sites.10 This is an 
important issue, as formation of non-covalent complexes 
with proteins is a key process in the transport and 
biodistribution of nonsteroidal antiinflammatory drugs in 
treated patients.  
In this context, although the photophysical properties 
of a number of antiinflammatory 2-arylpropionic acids (i. 
e. naproxen, benoxaprofen, carprofen, ketoprofen, 
tiaprofenic acid and  suprofen) have been previoulsy 
described,11 the first singlet excited state of FBP has not 
yet been fully characterised. Besides, there is no report on 
the lowest lying FBP triplet, in spite of its potential 
interest as a reporter of the physicochemical properties of 
its environment when complexed with biomolecules. A 
detailed investigation on the photophysical properties of 
FBP would also be helpful to understand its 
photoreactivity, which involves initial cleavage of the C-C 
bond α to the carbonyl group, ultimately leading to 
decarboxylation products.12 
In the present paper, the lowest singlet and triplet 
excited states of S-flurbiprofen have been examined, using 






Materials and solvents 
 
S-Flurbiprofen, benzophenone, acetophenone, chloranil, 
biacetyl and 1,3-cyclohexadiene were purchased from 
Aldrich. Their purity was checked by 1H NMR and HPLC 
analysis. 
The reagent grade solvents (methanol, hexane or 
acetonitrile) were obtained from Scharlau and used 
without further purification. Solutions of PBS 0.01 M (pH 
= 7.4) were  prepared by dissolving Sigma phosphate 




Optical spectra in different solvents were measured on a 




Emission spectra were recorded on an Edinburgh  FS900 
spectrofluorimeter system, provided with a M300 
monochromator in the wavelength range 200-900 nm. The 
samples were placed into 10 x 10 mm2 Suprasil quartz 
cells with a septum cap. The solutions were purged with 
nitrogen or oxygen for at least 15 min before the 
measurements. Fluorescence quantum yields were 

















at 281 nm and 0.30 at 254 nm in hexane).13 The 
absorbance of the samples at the excitation wavelength 
was kept below 0.1. Excitations and emission slits were 
maintained unchanged during the emission experiments. 
For time resolved fluorescence decay measurements, the 
conventional single photon counting technique was used. 
 
Laser flash photolysis experiments 
 
Laser flash photolysis experiments were performed by 
using a Q-switched Nd:YAG laser (Quantel Brilliant, 266 
nm or 355 nm for photosensitized experiments, 4 mJ per 
pulse, 5 ns fwhm) coupled to a mLFP-111 Luzchem 
miniaturized equipment. All transient spectra were 
recorded employing 10 x 10 mm2 quartz cells with 4 mL 
capacity and were bubbled during 30 min with N2, air or 
O2 before acquisition. The absorbance of the samples was 
kept between 0.20 and 0.25 at the laser wavelength.  
All the experiments were carried out at room 
temperature (22 ºC). 
 
General irradiation procedure 
 
Solutions of FBP (5 mM) in hexane, acetonitrile, 
methanol or PBS were irradiated for 16 h through quartz, 
inside a Luzchem multilamp photoreactor, with the light 
from 4 8W-lamps emitting mainly at 254 nm. The course 
of the reaction was followed by GC, GC-MS and 1H-
NMR; the degrees of conversion, the product distributions 
and the mass balances were determined using adequate 
standards. Photoreaction quantum yields were determined 
using phenylglyoxylic acid as actinometer.14 
 
Results and discussion 
 
Fluorescence characteristics of S-flurbiprofen 
 
Figure 1 shows the fluorescence spectrum of S-
flurbiprofen in PBS, when excited at 254 nm. The 
excitation spectrum for the emission at 300 nm is also 
shown in the figure. From the intersection between the 
two bands, after normalisation, a singlet energy of 99 kcal 




























No major changes in the shape of the peaks or in the 
position of the absorption maxima were observed when 
methanol, hexane or acetonitrile were employed as 
solvents.  Likewise, changing the excitation wavelength 
from 254 to 281 nm did not result in significant variations. 
Fluorescence quantum yields and lifetimes under different 
conditions are reported in Table 1. 
The fluorescence of FBP was sensitive to the presence 
of oxygen. Thus, when the samples were purged with O2 a 
significant decrease of the quantum yields and the 
lifetimes was observed; for instance, in acetonitrile 
solution (excitation at 281 nm) these values were found to 
be φF  = 0.15 and τF  = 1ns. 
 
Laser flash photolysis  measurements 
 
Figure  2 shows  the transient absorption spectra of S-
flurbiprofen (2.5 × 10-5 M) in PBS after 266 nm laser 
excitation. The band with maximum at 360 nm was 
assigned to the T-T absorption of  FBP and, as expected 





































 Fig. 1 Normalised excitation and emission spectra of S-
flurbiprofen in PBS.  
 
Fig. 2 Laser flash photolysis (266 nm excitation) of S-
flurbiprofen 2.5 × 10-5 M in PBS. A. Transient decay 
monitored at 360 nm, under N2. B . Spectra recorded 
under the same conditions, 14.4 µs (     ), 100 µs (    )   
and  310 µs (    ) after the laser pulse. C. Comparison 
between the spectra generated under N2, air and O2. 
 
 



























λem = 300nm λexc = 254 nm
















































Table 1 Photophysical properties of S-flurbiprofen in deaerated media 
Solvent φFa τF (ns) kF (s-1) φISC τT (µs) kISC (s-1) kNR (s-1) 
MeCN 0.20 (0.22) 1.7 1.2×108 0.71 31 4.2×108 4.1×107 
MeOH 0.27 (0.27) 1.5 1.8×108 0.70 33 4.7×108 2.0×107 
C6H14 0.32 (0.33) 2.0 1.6×108 0.65 15 3.3×108 1.0×107 
PBS 0.15 (0.15) 0.7 2.1×108 0.45 106 6.4×108 5.0×108 
a The data have been obtained upon excitation at 254 nm or 281 nm (in brackets) 
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The triplet lifetimes in deaerated media were found to 
be between 15 and 106 µs, depending on the solvent (see 
Table 1). The highest value was found in neutral aqueous 
buffer. The table also shows the intersystem crossing 
quantum yields that ranged between 0.45 and 0.71; they 
were calculated by the comparative method, based on 
energy transfer from known donors. The triplet lifetimes 
did not depend on the laser intensity (between 4 and 20 
mJ/pulse), ruling out a possible annihilation process. 
However, they decreased with increasing FBP 
concentration; the self-quenching constant in MeCN is 
given in Table 2. 
The T-T transient absorption of S-flurbiprofen was 
also generated by photosensitisation with benzophenone  
(BZP) and acetophenone. Thus, laser flash photolysis of 
BZP at 355 nm produced the typical BZP triplet with 
maximum at ca. 525 nm. In the presence of FBP, a fast 
disappearance of this band was observed, concomitantly 
with the growth of the 360 nm band, characteristic of FBP 
triplet (see Fig. 3). The rate constant of this energy 
transfer process was found to be 6.3 × 108 M-1 s-1 in 
MeCN at room temperature. The molar absorption 
coefficient of flurbiprofen triplet was determined using 
benzophenone as standard and assuming a value of 7800 
mol L-1 cm-1 at 525 nm for this compound.15 In MeCN, it 


























The ISC quantum yields of S-flurbiprofen in different 
solvents were calculated from the ∆A of the T-T bands of 
isoabsorptive solutions of BZP and FBP, the molar 
absorption coefficients of their triplets in acetonitrile (see 
above) and the known ISC quantum yield of BZP (ca. 1); 
they are shown in Table 1. From the values of φF, τF and 
φISC, it was possible to determine the rate constant of the 
different photophysical process (kF, kISC and kNR); they are 
also included in Table 1.  
Thus, the energy of the lowest triplet excited state of 
FBP must be lower than 69 kcal mol-1 (the triplet energy 
of BZP).16 In order to obtain a narrower range for this 
parameter, different triplet quenchers (i. e. 1,3-
cyclohexadiene, chloranil, and biacetyl) were used, and 
their interaction with the T-T absorption band was 
studied; the rate constants for these processes are given in 
Table 2. 
The above data indicate that, as expected for a 
biphenyl derivative, the triplet energy of FBP must be 
close to 65 kcal mol-1. Actually, triplet-triplet energy 
transfer to all the acceptors in Table 2 (ET between 50 and 


















When FBP was irradiated in different solvents, in the 
presence of oxygen, four products were detected in the 
photoreaction mixtures (see Chart 2 and Table 3). In 
general, the photoreaction quantum yields were low (0.03  






















The results obtained in the three organic solvents were 
in good agreement with the previously reported 
photochemical behaviour of FBP in methanol.12 However, 
formation of phenol 417 in aqueous solution was 
unexpected. Clearly, this photoproduct must arise via 
photonucleophilic aromatic substitution. A simplified 
reaction scheme is shown in Fig. 4. Similar processes have 
been described for other fluoroaromatics, including 
fluoroquinolone antibiotics.18 In general, deaeration of the 
irradiated solutions did not result in an enhanced 
photodegradation efficiency; this points to the first excited 
singlet as the reactive state. Accordingly, triplet 
sensitisation with benzophenone derivatives did not lead 
to significant amounts of products. Further support in 
favour of photoreaction from the excited singlet was 
provided by comparing the photophysical and the 
photochemical data. It is specially noteworthy that the 
fluorescence quantum yields and lifetimes, as well as the 
efficiency of intersystem crossing, were lower in aqueous 
media, where the photoreaction was faster and gave rise to 




Fig.  3  A. Growth and decay profiles monitored at 360 
nm and 520 nm upon 355 nm laser flash photolysis of 
benzophenone (2 × 10-3 M)  in the presence of S-
flurbiprofen (5 × 10-4  M) under N2-saturated conditions. 
B. Spectra of the transient intermediates generated 4 µs  
(     ), 5.3 µs (     ) and 8.5 µs (     ) after the laser pulse. 
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Table 2 Reactivity of S-flurbiprofen triplet in MeCN 
Substrate kq (M-1 s-1) 
Self-quenching 5.7 ×108 
O2 8.2 ×108 
1,3-Cyclohexadiene 1.0 × 1010 
Chloranila 9.0 × 109 
Biacetyl 5.0 × 109 




Table 3 Photochemistry of FBP at 254 nm 
Solvent Conversion 1 2 3 4 
MeCN 71 - 3 97 - 
MeOH 33 - 13 87 - 
C6H14 65 - 25 75 - 
PBS 100 50 - 23 27 
 
 





















In summary, the first excited singlet and triplet states of S-
flurbiprofen have been fully characterised, and the main 
processes leading to their deactivation have been 
identified. The excited state lifetimes and the quantum 
yields of the involved photophysical processes have been 
determined. Finally, steady state photolysis in aqueous 
medium has provided evidence for photonucleophilic 
aromatic substitution as an important photochemical 
pathway, in addition to the photodecarboxylation 
previously observed in organic solvents. 
When the photophysical behaviour of FBP is 
compared with that of biphenyl (BP, the parent 
chromphore), a number of properties are closely simirlar. 
They include the singlet and triplet energies (95-100 and 
65-70 kcal/mol, respectively), the position of the 
fluorescence band (λmax ca 300 nm) and the T-T 
absorption maxima (λmax = 360 nm). The quantum yields 
of fluorescence and intersystem crossing of  BP are known 
to be 0.15 and 0.84 respectively.19 This is in reasonable 
agreement with the values obtained for FBP (Table 1). 
However, the main differences between FBP and BP were 
the singlet and triplet lifetimes, that were found to be τF = 
15 ns and τT = 130 µs for the latter.19 The values 
determinded for FBP (Table 1) were clearly shorter, 
probably due to excited state deactivation via hydrogen 
bonding interactions involving the carboxylic group. As 
regards the comparison with related NSAIDs, FBP shares 
with naproxen (NPX) and carprofen (CP) the ability to 
generate detectable singlet and triplet excited species. By 
contrast, ketoprofen (KP), tiaprofenic acid (TPA) and 
suprofen (SP) do not exhibit reasonable flourescence, 
owing to a very efficient intersystem crossing. On the 
other hand, FBP (as NPX and CP) decarboxylates for its 
singlet excited state with low quantum yield (< 0.01), 
while in the case of KP, TPA and SUP decarboxylation 
occurs from the triplet excited state much more efficiently 
(φDEC > 0.4). Finally, FBP and CP undergo dehalogenation 
as an additional photoreaction pahtway.  
As a general conclusion, the results obtained for FBP 
in the present work suggest that the singlet and triplet 
excited states of FBP can be used as reporters to gain 
insigth into the nature of the binding sites of NSAIDs to 
receptors and transport proteins. The careful 
characterisation of both species and their 
medium/dependent properties provide the basis for future 
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